

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A ~~disposable container for a medicament or cosmetic agent for topical application, containing~~ method for topically applying a single dose of melatonin or of a melatonin derivative selected from the group consisting of 5-methoxytryptamine, 5-methoxytryptophan, 5-methoxytryptophol, 5-methoxyindole-3-acetic acid and 6-hydroxymelatonin, or salts or esters thereof, to a human scalp or hair, comprising,
(i) providing said human scalp or hair and
(ii) applying said single dose of melatonin or melatonin derivative, which
corresponds to a locally effective dose but ~~which~~ does not cause any systemic effect~~[[.]]~~ to said human scalp or hair, wherein the single dose is contained in a suitable disposable container and wherein the single dose corresponds to a daily dose.
2. (Currently Amended) The method of ~~container as claimed in claim 1,~~
characterized in that the single dose is 0.001 to 1.0 mg of melatonin or melatonin derivative.

3. (Currently Amended) The method of ~~container as claimed in~~ claim 1, characterized in that the single dose is 0.01 to 0.2 mg of melatonin or melatonin derivative.
4. Cancelled.
5. (Currently Amended) The method of ~~container as claimed in~~ claim 1, characterized in that the ~~agent~~ single dose is present as a liquid formulation.
6. (Currently Amended) The method of ~~container as claimed in~~ claim 5, characterized in that the liquid formulation has a concentration of 0.001 to 0.01 % (by weight) of melatonin.
7. (Currently Amended) The method of ~~container as claimed in~~ claim 6, characterized in that the liquid formulation has a concentration of 0.003 to 0.004% (by weight) of melatonin.
8. (Currently Amended) The method of ~~container as claimed in~~ claim 1, characterized in that the ~~agent~~ single dose contains, as sole active substance, melatonin or a melatonin derivative.
9. (Currently Amended) The method of ~~container as claimed in~~ claim 1, characterized in that the ~~agent~~ single dose contains, as active substances, a

combination of melatonin or a melatonin derivative together with biotin and/or ginkgo biloba.

10. (Currently Amended) The method of container ~~as claimed in claim 1~~, characterized in that the agent single dose contains, as active substance, a combination of melatonin or a melatonin derivative and vitamin A, vitamin A acid, ~~or another derivative of vitamin A~~.
11. (Currently Amended) The method of container ~~as claimed in claim 1~~, characterized in that ~~it~~ the container contains 2.5 to 3.5 ml of the agent.
12. (Currently Amended) The method of container ~~as claimed in claim 11~~, characterized in that ~~it~~ the container contains 2.9 to 3.2 ml of the agent.
13. (Currently Amended) The method of container ~~as claimed in claim 1~~, characterized in that the agent single dose is filled into the container under GMP conditions.
14. (Currently Amended) The method of container ~~as claimed in claim 1~~, characterized in that ~~it~~ the container is made of a plastic.

15. (Currently Amended) The method of ~~container as claimed in claim 14,~~
characterized in that ~~it~~ the container is made of polyethylene, polypropylene,
polyvinyl chloride, polystyrene or a mixture of these.
16. (Currently Amended) The method of ~~container as claimed in claim 1,~~
characterized in that ~~it~~ the container is colorless.
17. (Currently Amended) The method of ~~container as claimed in claim 1,~~
characterized in that ~~it~~ the container is colored.
18. (Currently Amended) The method of ~~container as claimed in claim 1,~~
characterized in that ~~it~~ the container is transparent.
19. (Currently Amended) The method of ~~container as claimed in claim 1,~~
characterized in that ~~it~~ the container is non-transparent.
20. (Currently Amended) The method of ~~container as claimed in claim 1,~~
characterized in that ~~it~~ the container has, on its head, a disposable closure piece
which is opened by turning it.
21. (Currently Amended) The method of ~~container as claimed in claim 1,~~
characterized in that, after opening, the ~~agent~~ single dose emerges only when
pressure is applied.

22. (Currently Amended) The method of ~~container as claimed in~~ claim 1, characterized in that ~~it~~ the container carries lettering either printed on or embossed and/or is provided with a label.
23. (Currently Amended) The method of claim 1, ~~An arrangement of several containers, as claimed in claim 1~~, wherein the container is comprised of an arrangement of containers which are connected to one another in a detachable manner.
24. (Currently Amended) The ~~arrangement as claimed in~~ method of claim 23, characterized in that 5 containers are connected to one another in a detachable manner.
25. (Currently Amended) The ~~arrangement as claimed in~~ method of claim 23, characterized in that 10 containers are connected to one another in a detachable manner.
26. (Currently Amended) The ~~arrangement as claimed in~~ method of claim 23, characterized in that ~~it~~ the container is packed into an aluminum bag.
27. (Currently Amended) The ~~arrangement as claimed in~~ method of claim 26, characterized in that the bag consists of an aluminum-containing laminated foil and additionally includes polyethylene, polyester and/or paper.

28. (Currently Amended) The ~~arrangement as claimed in~~ method of claim 26, characterized in that the aluminum bag is printed on and/or is provided with a label.
29. Cancelled.
30. (New) A method for promoting hair growth and/or treating alopecia in a human subject in need of such hair growth and/or treatment of alopecia, comprising, applying to the scalp or hair of the human subject a single dose of melatonin or melatonin derivative selected from the group consisting of 5-methoxytryptamine, 5-methoxytryptophan, 5-methoxytryptophol, 5-methoxyindole-3-acetic acid and 6-hydroxymelatonin, or salts or esters thereof, which corresponds to a locally effective dose but which does not cause any systemic effect, wherein the single dose is contained in a disposable container and wherein the single dose corresponds to a daily dose.
31. (New) A method according to claim 30, wherein the alopecia is selected from the group consisting of male pattern androgenetic alopecia, female pattern androgenetic alopecia, male pattern diffuse alopecia and female pattern diffuse alopecia.